ClinicalTrials.gg
Not yet recruitingNCT07551479TORCH-STARUpdated Apr 24, 2026

SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer

A Phase 3 interventional study of short-course radiaotherapy and long-course chemoradiaothearpy in Locally Advanced Rectal Cancer (LARC) and MSS (Microsatellite Stable), sponsored by Fudan University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Fudan University · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
612
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing Immune checkpoint inhibitors in Spinocerebellar Degenerations — 5 open to participants now, 5 under way, 2 of them phase 3. A drug class: Immune checkpoint inhibitors · Spinocerebellar Degenerations.

Planned enrollment
2nd of 12
612 · median 80
Started
2026
with 3 others
Phase 3
3 of 12
2 open now
Registered
10th of 12
by date
Lead sponsor
1 of 12
Fudan University

Among the 12 studies testing Immune checkpoint inhibitors in Spinocerebellar Degenerations, this one is the 2nd largest by planned enrollment, is one of 4 that started in 2026, is one of 3 in phase 3, and was the 10th registered.

Spinocerebellar Degenerations

49 studies on the registry are indexed under Spinocerebellar Degenerations; 15 are open to participants now.

Browse Spinocerebellar Degenerations studies →

Open to participants now

5 of the 12 studies testing Immune checkpoint inhibitors in Spinocerebellar Degenerations are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About Immune checkpoint inhibitors

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 9 Spinocerebellar Degenerations studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing Immune checkpoint inhibitors in Spinocerebellar Degenerations, or all of them as a file.
02

Study summary

In this prospective, multicentre, randomized phase III trial, 612 locally advanced rectal cancer (LARC, T3-4/N+M0) patients with at least one high-risk features (lower location (≤5cm), cT4, cN2, MRF+, EMVI+, TD+) will be included, and randomly assigned to TNT group and iTNT group (1:1). TNT group receives long-course chemoradiotherapy (50Gy/25Fx concurrent with oral capecitabine) followed by 6 cycles of CAPOX. iTNT group receives short-course radiotherapy (25Gy/5Fx) followed by 6 cycles of Serplulimab combined with CAPOX. After the efficacy evaluation, the patients who achieves clinical complete response (cCR) will be managed by a watch and wait (W\&W) protocol and non-cCR patients will be recommended surgery. The primary endpoint is 3-year event-free survival rate (3yEFS%). The secondary endpoints include the complete response (CR, pathological complete response [pCR] plus cCR) rate, 3-year organ preservation rate, 3-year disease-free survival rate (3yDFS%), 3-year local recurrence free survival rate (3yLRFS%), 3-year distant metastasis free survival rate (3yDMFS%), 3-year overall survival rate (3yOS%), grade 3-4 acute adverse effects (AE) rate, rate of surgical complications, anal functions and quality of life, etc.

03

Conditions studied

  • Locally Advanced Rectal Cancer (LARC)
  • MSS (Microsatellite Stable)

Keywords

  • Total Neoadjuvant Therapy
  • Immunotherapy
  • Survival Rate
  • Organ preservation
  • Locally advanced rectal cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 years old, female and male;
  2. Pathological confirmed adenocarcinoma;
  3. The distance from anal verge ≤ 10 cm;
  4. MSI/MMR status: MSS/pMMR;
  5. Clinical stage T3-4 and/or N+, without distance ;
  6. At least one of the following factors is present: distance from the anus ≤5 cm, cT4, cN2, positive cMRF, positive cEMVI, positive tumor deposit or positive lateral lymph node;
  7. ≥ 70;
  8. No radiotherapy, chemotherapy, immunotherapy, or any other anti-tumor therapy had been administered prior to enrollment;
  9. Baseline blood and biochemical indicators meet the following criteria: neutrophils ≥ 1.5 × 10\^9/L, ≥ 90 g/L, ≥ 100 × 10\^9/L, / AST ≤ 2.5 , Cr ≤ 1 ULN;
  10. With good compliance and signed the consent form.

Exclusion criteria

Exclusion Criteria

  1. Pregnancy or breast-feeding women;
  2. Known history of other within 5 years;
  3. Known history of severe neurological or mental illness (such as schizophrenia, dementia or epilepsy);
  4. Current severe cardiac disease (cardiac dysfunction and arrhythmia), renal dysfunction and liver dysfunction;
  5. Acute cardiac infarction or cerebral ischemic stroke occurred within 6 months before recruitment;
  6. Uncontrolled infection which needs systemic therapy;
  7. Active disease or immunodeficiencies, known history of organ transplantation or systematic use of agents;
  8. Known history of (HIV) infection (i.e., HIV 1 to 2 antibody positive), active syphilis infection, active pulmonary tuberculosis infection;
  9. Allergic to any component of the therapy.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
612 participants (estimated)

Study arms

  • Other
    TNT group

    TNT group receives long-course chemoradiotherapy (concurrent with oral capecitabine) followed by 6 cycles of CAPOX.

    Radiation: long-course chemoradiaothearpy · Drug: Capecitabine · Drug: Oxaliplatin

  • Experimental
    iTNT group

    iTNT group receives short-course radiotherapy (25Gy/5Fx) followed by 6 cycles of Serplulimab combined with CAPOX.

    Radiation: short-course radiaotherapy · Drug: Capecitabine · Drug: Oxaliplatin · Drug: PD-1 inhibitor

Interventions

06

What researchers measure

Primary outcomes

  1. 3 year event-free survival rate

    Rate of 3 year event free survival

    Time frame: From date of randomization until the date of first documented early local failure, disease progression during neoadjuvant therapy, pelvic recurrence, distant metastasis, or death, whichever came first, assessed up to 36 months.

Secondary outcomes

  1. Complete response (CR) rate

    Rate of complete response (CR), including the rate of pathologic complete response (pCR) after surgery and the rate of cCR with W\&W strategy.

    Time frame: 1 month after the surgery or the decision of W&W

  2. 3 year organ preservation rate

    3 year organ preservation rate

    Time frame: From date of randomization until the resection of rectum or anus, assessed up to 36 months.

  3. 3 year disease free survival rate

    Rate of 3 year disease free survival

    Time frame: From date of randomization until the date of first documented recurrence and metastasis after the completion of treatment or death from any cause, whichever came first, assessed up to 36 months.

  4. 3 year local recurrence free survival rate

    Rate of 3 year local recurrence free survival

    Time frame: From date of randomization until the date of first documented pelvic failure, assessed up to 36 months.

  5. 3 year distant metastasis free survival rate

    Rate of 3 year distant metastasis free survival

    Time frame: From date of randomization until the date of first documented distant metastasis, assessed up to 36 months.

  6. 3 year overall survival rate

    Rate of 3 year overall survival

    Time frame: From date of randomization until the date of death from any cause, assessed up to 36 months.

  7. Grade 3-4 adverse effects rate

    Rate of chemotherapy, radiotherapy and immunotherapy related adverse events

    Time frame: From date of randomization until 3 months after the completion neoadjuvant therapy

  8. Rate of surgical complications

    Rate of surgical complications

    Time frame: The surgical complications were assessed within 1 year after the surgery.

  9. Low Anterior Resection Syndrome Score

    Evaluating the anal function using Low Anterior Resection Syndrome (LARS) score(range 0-42, with higher scores representing worse anal function)

    Time frame: From date of randomization until five years after the completion of treament.

  10. Wexner Continence Grading Scale

    Evaluating the anal function using Wexner Continence Grading Scale (range 1-20, with higher scores representing worse anal function)

    Time frame: From date of randomization until five years after the completion of treament.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for Dec 2032, 79 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2026
First posted
Apr 24, 2026
StartEst.
May 1, 2026
Primary completionEst.
Dec 31, 2032
CompletionEst.
Dec 31, 2035
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07551479
Lead sponsor
Fudan University
Responsible party
Zhen Zhang (Professor, Fudan University) — Principal investigator
First posted
Apr 24, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Dec 31, 2032 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Apr 24, 2026

Study contacts

Zhen Zhang, MD, PhD
Contact
zhen_zhang@fudan.edu.cn
18801735029

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immune checkpoint inhibitors

Start the discussion